13 completed. 6 Phase 1, 4 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 4 | Completed 4 |
Follow valspodar: new trials by email Literature Review of valspodar trials Research Report on valspodar
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia cytarabine, daunorubicin hydrochloride, etoposide - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 3 | Completed | National Cancer Institute (NCI) | 720 | 2000-11-01 | 2013-06-04 |
| S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia filgrastim, sargramostim, cytarabine - Leukemia | Phase 2 | Completed | SWOG Cancer Research Network | 55 | 2000-02-01 | 2015-03-06 |
| Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome cytarabine, daunorubicin hydrochloride, etoposide - Leukemia, Myelodysplastic Syndromes | Phase 3 | Completed | Leukemia Research Fund | 2000 | 1998-12-01 | 2013-12-18 |
| Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers pegylated liposomal doxorubicin hydrochloride, PSC 833 - Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Washington University School of Medicine | 14 | 1998-03-01 | 2013-04-12 |
| Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia cytarabine, daunorubicin hydrochloride, etoposide - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 3 | Completed | National Cancer Institute (NCI) | 640 | 1998-01-01 | 2013-06-04 |
| Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer paclitaxel, valspodar - Breast Cancer | Phase 2 | Completed | Eastern Cooperative Oncology Group | 36 | 1997-08-14 | 2023-06-07 |
| Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma dexamethasone, doxorubicin hydrochloride, valspodar - Multiple Myeloma and Plasma Cell Neoplasm | Phase 3 | Completed | Eastern Cooperative Oncology Group | 1997-06-30 | 2023-06-15 | |
| Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia ara-C, Daunorubicin, Etoposide - Leukemia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 410 | 1997-02-01 | 2012-11-30 |
| A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer PSC 833, vinblastine - Kidney Neoplasms, Neoplasm Metastasis | Phase 1 | Completed | National Cancer Institute (NCI) | 46 | 1997-02-01 | 2008-03-04 |
| Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia etoposide, mitoxantrone hydrochloride, valspodar - Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 3 | 1997-01-01 | 2013-02-01 |
| Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer paclitaxel, valspodar - Breast Cancer | Phase 2 | Completed | City of Hope Medical Center | 70 | 1996-06-01 | 2010-01-06 |
| A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 PSC 833, paclitaxel - Breast Cancer, Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 52 | 1994-03-01 | 2008-03-04 |
| A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833 PSC 833 - Breast Cancer, Kidney Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 1992-09-01 | 2008-03-04 |
Leukemia, Erythroblastic, Acute (5) · Leukemia, Megakaryoblastic, Acute (5) · Leukemia, Monocytic, Acute (5) · Leukemia, Myeloid, Acute (5) · Leukemia, Myelomonocytic, Acute (5) · Breast Neoplasms (4) · Leukemia (4) · Congenital Abnormalities (3) · Kidney Neoplasms (2) · Lymphoma (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · AIDS-related Kaposi sarcoma (1) · Anemia, Refractory, with Excess of Blasts (1) · Carcinoma, Renal Cell (1)
National Cancer Institute (NCI) (7) · Eastern Cooperative Oncology Group (2) · City of Hope Medical Center (1) · Leukemia Research Fund (1) · SWOG Cancer Research Network (1) · Washington University School of Medicine (1)
United States (12) · Canada (4) · Australia (1) · United Kingdom (1)
Alan K. Burnett, MD, FRCP (1) · Chaim Shustik, MD (1) · Gary V.H. Dahl, MD (1) · James H. Doroshow, MD (1) · Jonathan E. Kolitz, MD (1) · Jonathan Kolitz (1) · Karl H. Hanson, MD (1) · Maria Baer (1) · Paula M. Fracasso, MD, PhD (1) · Pieter Sonneveld, MD, PhD (1) · Richard A. Larson, MD (1) · Robert W. Carlson, MD (1) · Thomas R. Chauncey, MD, PhD (1) · William R. Friedenberg, MD (1)
PMID 31375516, PMID 36184192, PMID 11331327, PMID 11585760, PMID 12750167, PMID 15514371, PMID 16275934, PMID 16419071, PMID 16670265, PMID 17315155, PMID 19291085, PMID 20209646, PMID 20522709, PMID 24383844, PMID 25527568, PMID 34162404
U10CA031946 (3), U01CA063265 (1), U10CA032102 (1)